Christopher Jacklin, Co-founder & CEO, Lucero
I dove into life science in 2019 by accident - it blew my mind.
It was a completely new world to me that was pushing boundaries in ways that I didn’t know existed, let alone were possible.
The area of 3D cell culture particularly caught my attention - novel in-vitro cell-model systems that are used to predict the efficacy and toxicity of drugs very early in the drug development timeline.
How they could transform the pharmaceutical industry by vastly expanding our understanding of complex diseases, helping tailor new drugs for specific patient subgroups, and decreasing the industry’s dependence on animal testing.
My team and I recognized that if the industry was going to fully adopt these new models they also needed new tools to work with them - to culture, mature, handle, and analyze them.
Today, we are working to enable drug developers to use 3D cell models at scale to increase drug success rates and reduce dependency on animal testing.
Disclosure information not submitted.
Lucero Bio: Enabling near-patient drug testing using ultra-miniaturized spheroids
Tuesday, May 28, 2024
13:50 – 14:00 CEST